Rain Therapeutics Inc. (NASDAQ: RAIN) reported Q2 EPS of ($0.61), $0.10 worse than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Rain Therapeutics Inc. (RAIN) click here.